Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bronchoscopy & lung nodule cases in New Mexico: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 142 | 40% |
| 2020 | 0 | 71 | 43% |
| 2021 | 2 | 126 | 46% |
| 2022 | 1 | 117 | 50% |
| 2023 | 2 | 143 | 53% |
| 2024 | 4 | 210 | 54% |
| 2025 from claims | – | 371 300–436 | 54% |
| 2026 forecast | – | 401 314–504 | 55% |
| 2027 forecast | – | 437 324–578 | 55% |
| 2028 forecast | – | 477 338–658 | 56% |
| 2029 forecast | – | 520 353–745 | 56% |
| 2030 forecast | – | 566 371–840 | 56% |
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Mexico; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| Forecast, Medicare FFS | Hospital outpatient |
|---|---|
| 2026 · ~400 | ~400 |
| 2027 · ~440 | ~440 |
| 2028 · ~480 | ~480 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 119 | 8,499+11%/yr | +11%/yr | 2.6 | 2% | 16,800 in 2030+12%/yr |
| Arizona | 38 | 3,079+16%/yr | +16%/yr | 4.2 | 0% | 5,590 in 2030+10%/yr |
| Washington | 31 | 1,779+2.1%/yr | +2.1%/yr | 2.3 | 0% | 2,570 in 2030+6.3%/yr |
| Colorado | 18 | 1,328+5.9%/yr | +5.9%/yr | 2.8 | 0% | 2,020 in 2030+7.2%/yr |
| Oregon | 10 | 796+5.6%/yr | +5.6%/yr | 1.9 | 0% | 1,500 in 2030+11%/yr |
| Nevada | 11 | 545+13%/yr | +13%/yr | 1.9 | 0% | 870 in 2030+8.2%/yr |
| Utah | 6 | 444+15%/yr | +15%/yr | 2.1 | 0% | 960 in 2030+14%/yr |
| Idaho | 5 | 286+3%/yr | +3%/yr | 1.4 | 0% | 650 in 2030+15%/yr |
| Montana | 5 | 277+1.2%/yr | +1.2%/yr | 1.5 | 0% | 310 in 2030+1.7%/yr |
| Hawaii | 6 | 241+24%/yr | +24%/yr | 1.9 | 0% | 590 in 2030+16%/yr |
| Alaska | 2 | 179+25%/yr | +25%/yr | 1.5 | 0% | 660 in 2030+24%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 87 | 16,821−4.2%/yr | −4.2%/yr | 75.90.7× | 40% | 17,500 in 2030+0.7%/yr |
| ERCP & endoscopic ultrasound | 8 | 365−15%/yr | −15%/yr | 1.60.5× | 0% | 390 in 2030+1.1%/yr |
Bronchoscopy & lung nodule in every state, and its device makers · Every procedure market in New Mexico · Every state · Compare with California
Johnson & Johnson MedTech leads with 39% of company spending on these surgeons in 2025, +39 pts on 2024.
In 2025, 11 companies reported engagement with New Mexico’s surgeons worth $4,021 in consulting, speaking, meals and travel tied to these products, about $1,005 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.